ALK and non-small cell lung carcinoma: Similarly, the BRIGHTSTAR trial (NCT03707938) is investigating the role of brigatinib with local consolidative therapy in patients who have ALK-rearranged advanced oligometastatic or polymetastatic NSCLC, with promising early results presented at the 2020 American Society of Clinical Oncology Annual Meeting [55,56].